[Company Overview and Q2 Highlights](index=1&type=section&id=Company%20Overview%20and%20Q2%20Highlights) Senseonics Holdings, Inc. is a medical technology company focused on long-term implantable CGM systems, achieving significant Q2 growth in US new patient starts and securing substantial funding for product development and market expansion [Company Profile](index=1&type=section&id=Company%20Profile) Senseonics Holdings, Inc. is a medical technology company focused on developing and manufacturing long-term implantable continuous glucose monitoring (CGM) systems for diabetes patients, with key products including Eversense 365 and Eversense E3 - Senseonics Holdings, Inc. is dedicated to developing and manufacturing long-term implantable continuous glucose monitoring (CGM) systems for diabetes patients[1](index=1&type=chunk)[11](index=11&type=chunk) - The company's CGM systems, Eversense® 365 and Eversense® E3, feature a small, fully implantable subcutaneous sensor that automatically transmits glucose data every 5 minutes to a user's smartphone application via a smart transmitter[11](index=11&type=chunk) [Recent Highlights & Accomplishments](index=1&type=section&id=Recent%20Highlights%20%26%20Accomplishments) The company focused on the US launch of Eversense 365 in Q2, achieving a **79% year-over-year** increase in new patient starts, alongside expanding DTC advertising, transitioning providers to Eon Care, securing CMS Medicare reimbursement for Eversense 365, and signing a commercial development agreement with Sequel Med Tech to integrate AID systems, while also raising **$77.8 million** through public and private offerings - US new patient starts increased by **79% year-over-year**[1](index=1&type=chunk)[5](index=5&type=chunk) - Expanded direct-to-consumer (DTC) advertising campaigns, with the first month of enhanced activity generating **50% more leads** than the average of the preceding three months[5](index=5&type=chunk) - Completed the transition of service providers to Eon Care, with **38 providers** now supporting patient implants[5](index=5&type=chunk) - CMS updated the Medicare Physician Fee Schedule, providing a full year of Medicare benefit reimbursement for Eversense 365[5](index=5&type=chunk) - Signed a commercial development agreement with Sequel Med Tech to integrate the twiist™ automated insulin delivery (AID) system with Eversense 365, with an anticipated launch in Q4[5](index=5&type=chunk) - Raised **$57.5 million** through a public offering and **$20.3 million** from an Abbott private placement, totaling **$77.8 million** in gross proceeds, to support the continued promotion of Eversense 365 and pipeline product development[5](index=5&type=chunk) [Second Quarter 2025 Financial Performance](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Performance) The company reported a **37% year-over-year** revenue increase to **$6.6 million** in Q2 2025, with significantly improved gross profit and a reduced net loss of **$14.5 million** due to higher margins and lower R&D expenses [Revenue Analysis](index=1&type=section&id=Revenue%20Analysis) Total revenue for Q2 2025 increased by **37% year-over-year** to **$6.6 million**, primarily driven by a **79% growth** in US new patient starts, with significant US revenue increase offsetting a slight decline in ex-US revenue Q2 2025 Revenue Performance (2025 vs. 2024) | Metric | Q2 2025 (million USD) | Q2 2024 (million USD) | Year-over-Year Change | | :----- | :-------------------- | :-------------------- | :-------------------- | | Total Revenue | $6.6 | $4.9 | +37% | | US Revenue | $4.9 | $3.0 | +63.3% | | Ex-US Revenue | $1.7 | $1.9 | -10.5% | [Gross Profit](index=1&type=section&id=Gross%20Profit) Gross profit for Q2 2025 significantly increased to **$3.1 million** from **$0.3 million** in Q2 2024, primarily due to improved 365-day product margins and a one-time benefit from the recovery of previously expensed VAT Q2 2025 Gross Profit (2025 vs. 2024) | Metric | Q2 2025 (million USD) | Q2 2024 (million USD) | Year-over-Year Change | | :----- | :-------------------- | :-------------------- | :-------------------- | | Gross Profit | $3.1 | $0.3 | +933.3% | - The increase in gross profit was primarily driven by improved 365-day product margins and a one-time benefit from the recovery of previously expensed value-added tax (VAT)[5](index=5&type=chunk)[6](index=6&type=chunk) [Operating Expenses](index=2&type=section&id=Operating%20Expenses) In Q2 2025, Research and Development expenses decreased year-over-year, while Selling, General and Administrative expenses increased year-over-year [Research and Development (R&D) Expenses](index=2&type=section&id=Research%20and%20Development%20%28R%26D%29%20Expenses) R&D expenses for Q2 2025 decreased by **$3.1 million** year-over-year to **$7.7 million**, primarily due to reduced clinical study expenditures and consulting fees following the completion of the 365-day product trial Q2 2025 Research and Development Expenses (2025 vs. 2024) | Metric | Q2 2025 (million USD) | Q2 2024 (million USD) | Year-over-Year Change | | :----- | :-------------------- | :-------------------- | :-------------------- | | R&D Expenses | $7.7 | $10.8 | -28.6% | - The decrease in R&D expenses was primarily due to reduced clinical study expenditures and consulting fees following the completion of the 365-day product trial[6](index=6&type=chunk) [Selling, General and Administrative (SG&A) Expenses](index=2&type=section&id=Selling%2C%20General%20and%20Administrative%20%28SG%26A%29%20Expenses) SG&A expenses for Q2 2025 increased by **$0.7 million** year-over-year to **$9.7 million**, primarily due to higher sales commission expenses from increased consignment sales and increased personnel costs supporting the Eon Care implanter network Q2 2025 Selling, General and Administrative Expenses (2025 vs. 2024) | Metric | Q2 2025 (million USD) | Q2 2024 (million USD) | Year-over-Year Change | | :----- | :-------------------- | :-------------------- | :-------------------- | | SG&A Expenses | $9.7 | $9.0 | +7.8% | - The increase in expenses was primarily driven by higher sales commission expenses due to increased consignment sales and increased personnel costs supporting the Eon Care implanter network[7](index=7&type=chunk) [Net Loss and Earnings Per Share (EPS)](index=2&type=section&id=Net%20Loss%20and%20Earnings%20Per%20Share%20%28EPS%29) Net loss for Q2 2025 decreased by **$5.8 million** to **$14.5 million**, resulting in a loss per share of **$0.02**, an improvement from Q2 2024's net loss of **$20.3 million** (loss per share of **$0.03**), primarily due to improved gross margins from US Eversense 365 sales and reduced R&D costs Q2 2025 Net Loss and Loss Per Share (2025 vs. 2024) | Metric | Q2 2025 (million USD) | Q2 2024 (million USD) | Year-over-Year Change | | :----- | :-------------------- | :-------------------- | :-------------------- | | Net Loss | $(14.5) | $(20.3) | -28.57% | | Loss Per Share | $(0.02) | $(0.03) | -33.33% | - The reduction in net loss was primarily attributable to improved gross margins from US Eversense 365 sales and an overall decrease in R&D costs[8](index=8&type=chunk) [Full Year 2025 Financial Outlook](index=2&type=section&id=Full%20Year%202025%20Financial%20Outlook) Senseonics projects full-year 2025 global net revenue of approximately **$34 million to $38 million**, with the global patient base expected to double, revenue generation weighted towards the second half, particularly Q4, due to Eversense 365 annual reorder dynamics, and full-year gross margin anticipated to improve to **32.5% to 37.5%**, with operating cash usage around **$60 million** Full Year 2025 Financial Outlook | Metric | Outlook | | :----- | :------ | | Global Net Revenue | ~$34-38 million USD | | Global Patient Base | Approximately double | | Revenue Distribution | ~1/3 H1, ~2/3 H2 (Q4 weighted higher) | | Gross Margin | 32.5% - 37.5% | | Operating Cash Usage | ~$60 million USD | - The financial outlook considers the timing and specifications of Eversense 365 regulatory approvals and commercial transitions outside the US, DTC marketing expenditure plans, other sales and marketing initiatives, the utilization and impact of patient assistance programs, and the ongoing progress of the Eversense E3 to Eversense 365 reimbursement transition[9](index=9&type=chunk) [Product and Partner Information](index=2&type=section&id=Product%20and%20Partner%20Information) The company's Eversense CGM systems offer long-term glucose monitoring for diabetes patients, supported by strategic partnerships with Ascensia Diabetes Care and its parent company, PHC Holdings Corporation, for global distribution and healthcare solutions [About Eversense Continuous Glucose Monitoring (CGM) Systems](index=2&type=section&id=About%20Eversense%20Continuous%20Glucose%20Monitoring%20%28CGM%29%20Systems) Eversense CGM systems (Eversense 365 and E3) are designed for diabetes patients aged 18 and older, offering continuous glucose monitoring for up to **365 and 180 days**, respectively, serving as a replacement for fingerstick measurements in diabetes treatment decisions, though calibration is still required, with sensor insertion and removal performed by healthcare providers as prescription devices - Eversense® 365 and Eversense® E3 CGM systems are indicated for diabetes patients aged 18 and older, providing continuous glucose measurements for up to **365 and 180 days**, respectively[12](index=12&type=chunk) - These systems can be used to replace fingerstick blood glucose measurements for diabetes treatment decisions, though Eversense 365 requires one fingerstick calibration per week after day 14, and Eversense E3 requires one per day after day 21[12](index=12&type=chunk) - Sensor insertion and removal procedures are performed by healthcare providers, and Eversense CGM systems are prescription devices[12](index=12&type=chunk) [Strategic Partnerships](index=3&type=section&id=Strategic%20Partnerships) Senseonics maintains a global exclusive distribution partnership with Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation, collaborating to improve the lives of diabetes patients through innovative solutions [Ascensia Diabetes Care](index=3&type=section&id=Ascensia%20Diabetes%20Care) Ascensia Diabetes Care is Senseonics' global exclusive distribution partner for Eversense CGM systems, empowering diabetes patients with innovative solutions and owning the CONTOUR® blood glucose monitoring system portfolio, operating in over **100 countries** with approximately **1,400 employees** - Ascensia Diabetes Care is the global exclusive distribution partner for Senseonics Eversense® continuous glucose monitoring systems[13](index=13&type=chunk) - Ascensia also owns the globally recognized CONTOUR® blood glucose monitoring system portfolio, operating in over **100 countries** with approximately **1,400 employees**[13](index=13&type=chunk)[14](index=14&type=chunk) [PHC Holdings Corporation](index=3&type=section&id=PHC%20Holdings%20Corporation) PHC Holdings Corporation is a global healthcare company and the parent of Ascensia Diabetes Care, developing, manufacturing, selling, and servicing solutions in diabetes management, healthcare, life sciences, and diagnostics through its subsidiaries, with **353.9 billion JPY** in consolidated net sales for FY2024 and products distributed in over **125 countries** - PHC Holdings Corporation is a global healthcare company and the parent company of Ascensia Diabetes Care Holdings AG[15](index=15&type=chunk) - The PHC Group reported consolidated net sales of **353.9 billion JPY** for fiscal year 2024, with products and services distributed in over **125 countries** globally[15](index=15&type=chunk) [Condensed Consolidated Financial Statements](index=5&type=section&id=Condensed%20Consolidated%20Financial%20Statements) The company's balance sheet as of June 30, 2025, shows increased total assets and stockholders' equity, while the statements of operations reflect improved gross profit and reduced net loss for both the three and six months ended June 30, 2025 [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets increased to **$150.3 million** from **$100.4 million** at December 31, 2024, driven by higher short-term investments and cash, while total liabilities decreased from **$79.3 million** to **$55.6 million** due to reduced short-term notes payable, and stockholders' equity shifted from a **$16.6 million** deficit to a **$94.7 million** positive balance Condensed Consolidated Balance Sheets (Selected Items) | Metric (thousand USD) | June 30, 2025 | December 31, 2024 | Change | | :-------------------- | :------------ | :---------------- | :----- | | Cash and Cash Equivalents | $31,518 | $74,597 | $(43,079) | | Short-term Investments, net | $94,894 | — | $94,894 | | Total Current Assets | $141,588 | $91,438 | $50,150 | | Total Assets | $150,274 | $100,438 | $49,836 | | Total Current Liabilities | $14,776 | $38,849 | $(24,073) | | Total Liabilities | $55,554 | $79,337 | $(23,783) | | Total Stockholders' Equity (Deficit) | $94,720 | $(16,555) | $111,275 | [Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For the three months ended June 30, 2025, total revenue was **$6.6 million**, gross profit was **$3.1 million**, and net loss was **$14.5 million** (loss per share of **$0.02**), while for the six months, total revenue was **$12.9 million**, gross profit was **$4.6 million**, and net loss was **$28.8 million** (loss per share of **$0.04**), indicating significant improvement in gross profit and reduced net loss compared to the prior year Unaudited Condensed Consolidated Statements of Operations (Selected Items) | Metric (thousand USD) | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :-------------------- | :------ | :------ | :------ | :------ | | Total Revenue | $6,649 | $4,865 | $12,906 | $9,912 | | Gross Profit | $3,121 | $298 | $4,626 | $633 | | Operating Loss | $(14,323) | $(19,493) | $(27,811) | $(37,724) | | Net Loss | $(14,501) | $(20,287) | $(28,760) | $(39,164) | | Basic Net Loss Per Share | $(0.02) | $(0.03) | $(0.04) | $(0.06) | [Additional Information](index=2&type=section&id=Additional%20Information) This section provides details on the Q2 2025 conference call, outlines forward-looking statements subject to various risks, and lists investor contact information [Conference Call and Webcast Information](index=2&type=section&id=Conference%20Call%20and%20Webcast%20Information) Senseonics held a conference call on August 6, 2025, at 4:30 PM ET to discuss financial results and recent business developments, providing webcast and dial-in access - The company held a conference call on August 6, 2025, at 4:30 PM ET to discuss financial results and recent business developments, with investor participation available via webcast or dial-in[10](index=10&type=chunk) [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) The report contains forward-looking statements regarding future expectations, plans, and prospects, particularly concerning revenue, gross margin, cash flow, and global customer base forecasts, as well as product development, which are subject to various significant factors and risks that could cause actual results to differ materially - The press release contains forward-looking statements regarding future expectations, plans, and prospects, including projections for fiscal year 2025 revenue, gross margin, cash flow, and global customer base[16](index=16&type=chunk) - Actual results may differ materially from forward-looking statements due to various significant factors, including uncertainties related to reliance on commercialization partners, regulatory processes, new technology development, and economic conditions, with detailed information outlined in reports filed with the SEC[17](index=17&type=chunk) [Investor Contact](index=4&type=section&id=Investor%20Contact) Senseonics investor contact information is provided through LifeSci Advisors - Investors can contact Senseonics Investor Relations through Jeremy Feffer at LifeSci Advisors via investors@senseonics.com[18](index=18&type=chunk)

Company Overview - Senseonics Holdings, Inc. is a medical technology company focused on developing and manufacturing long-term implantable continuous glucose monitoring (CGM) systems for diabetes management [3] - The company's CGM systems, Eversense 365 and Eversense E3, feature a small sensor that is implanted under the skin and communicates with a smart transmitter worn externally, sending glucose data to a mobile app every 5 minutes [3] Financial Results Announcement - Senseonics plans to release its second quarter 2025 financial results after market close on August 6, 2025 [1] - A conference call to review the company's performance for the second quarter 2025 will take place at 4:30 p.m. (Eastern Time) on the same day, with a webcast available on the company's website [2]

Core Viewpoint - Senseonics Holdings (SENS) has experienced significant selling pressure, resulting in a 5.7% decline over the past four weeks, but analysts anticipate improved earnings in the near future [1] Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if a stock is oversold, with a reading below 30 indicating oversold conditions [2] - SENS has an RSI reading of 23.99, suggesting that the heavy selling may be exhausting, indicating a potential rebound towards equilibrium [5] Fundamental Indicators - There is a strong consensus among sell-side analysts to raise earnings estimates for SENS, leading to a 26.3% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7] - SENS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]

Company Overview - Senseonics Holdings, Inc. is a medical technology company focused on developing and manufacturing long-term implantable continuous glucose monitoring (CGM) systems for diabetes management [5] Upcoming Event - The company will host an in-person and virtual analyst event on June 21, 2025, at 8:00 am CT during the American Diabetes Association 85th Scientific Sessions [1] - The event will feature discussions on the next-generation Eversense® 365 CGM system, which has been approved by the FDA for individuals aged 18 and older [2] Event Details - Company management will present alongside Brian Hansen from Ascencia Diabetes Care, who will discuss the commercial launch of Eversense 365, and Gary Graf from Cotton-O'Neil Diabetes and Endocrinology Center, who will share insights on the Eversense system and its insertion procedure [3] - The event will also cover a recently announced partnership with Sequel to integrate with the twiist automated insulin delivery pump and plans to advance the pipeline of implantable CGM technology [3] - A live question and answer session will follow the formal presentations [4]

Core Viewpoint - Senseonics Holdings, Inc. has successfully closed a public offering of 115 million shares at a price of $0.50 per share, raising gross proceeds of $57.5 million before expenses [1][2]. Group 1: Public Offering Details - The public offering included the full exercise of an option by underwriters to purchase an additional 15 million shares [1]. - The offering was conducted under a "shelf" registration statement that became effective on September 12, 2023 [5]. - The offering was managed by TD Cowen and Barclays as joint book-running managers, with RBC Capital Markets and Lake Street as bookrunners [4]. Group 2: Private Placement with Abbott Laboratories - In conjunction with the public offering, Senseonics entered into a stock purchase agreement with Abbott Laboratories, issuing shares representing 4.99% of its outstanding common stock [3]. - Abbott acquired 40,539,265 shares for approximately $20.3 million before offering expenses [3]. Group 3: Use of Proceeds - The net proceeds from both the public offering and private placement will be used to fund the launch of Eversense 365, ongoing product development, working capital, and general corporate purposes [4][9]. Group 4: Company Overview - Senseonics is focused on developing long-term implantable continuous glucose monitoring systems aimed at improving the lives of individuals with diabetes [7]. - The company's Eversense® CGM systems feature a small sensor that is implanted under the skin and communicates with a smart transmitter, sending glucose data to a mobile app every 5 minutes [7].

Core Insights - Senseonics has been under observation for several years, with a previous bullish article published in March 2021, which did not yield the expected positive results for investors [1] - The investment strategy employed focuses on a value-oriented approach while incorporating reasonably valued growth stocks, emphasizing the importance of buying quality companies at fair prices [1] - The portfolio has shown significant performance variations over the years, with a total return of 4,114% since inception in 2016, and an internal rate of return (IRR) of 51.54% per year [1] Portfolio Performance Summary - 2016: Portfolio return of 1.28%, compared to NASDAQ's 7.50%, resulting in a delta of -6.22% [1] - 2017: Portfolio return of 49.40%, NASDAQ at 28.23%, delta of +21.17% [1] - 2018: Portfolio return of 84.91%, NASDAQ at -3.88%, delta of +88.79% [1] - 2019: Portfolio return of -1.08%, NASDAQ at 35.23%, delta of -36.31% [1] - 2020: Portfolio return of 173.62%, NASDAQ at 43.63%, delta of +129.99% [1] - 2021: Portfolio return of 37.84%, NASDAQ at 21.40%, delta of +16.44% [1] - 2022: Portfolio return of 20.93%, NASDAQ at -33.10%, delta of +54.03% [1] - 2023: Portfolio return of 87.60%, NASDAQ at 43.42%, delta of +44.18% [1] - 2024: Portfolio return of 77.98%, NASDAQ at 29.83%, delta of +48.15% [1]

Core Viewpoint - The article discusses the recent funding activities of Senseonics Holdings, including a $50 million public offering and a $25 million private placement with Abbott, aimed at supporting the commercialization and development of its Eversense 365 continuous glucose monitoring (CGM) system [1][3]. Funding Structure and Use - Senseonics plans to raise approximately $50 million through a public offering, with an additional $25 million from Abbott, totaling $75 million (around 540 million RMB) [1][3]. - The funds will be allocated for commercial expansion of Eversense 365, product development, operational expenses, and debt repayment [3]. Strategic Implications of Abbott's Investment - Abbott will hold approximately 4.99% of Senseonics' common stock post-transaction, indicating a strategic partnership rather than a controlling stake [4]. - The investment allows Abbott to strengthen its position in the evolving CGM market, where competition is increasing from companies like Dexcom and Medtronic [4][6]. - Abbott's investment is seen as a proactive measure to counter potential market disruptions and to diversify its CGM product offerings [6][7]. Eversense 365 Overview - Eversense 365 is the first FDA-approved implantable CGM system that lasts for 365 days, significantly reducing the burden of daily management for patients [8][12]. - The system has a mean absolute relative difference (MARD) of 8.8%, with a 90% sensor function retention rate over a year [12][14]. Competitive Advantages of Eversense 365 - Eversense 365 offers a longer sensor life compared to traditional CGMs, which require frequent replacements every 10 to 14 days [13]. - The system features a removable transmitter, allowing for flexibility in daily activities and reducing skin irritation [15][17]. - It includes built-in alerts for high and low blood sugar levels, enhancing patient safety [16]. Future Product Development - Senseonics is developing two additional products, Gemini and Freedom, which aim to further enhance its product line and adapt to future market needs [11][19]. - These products are expected to play significant roles in closed-loop systems, providing Abbott with strategic options for future growth [7].

Core Viewpoint - Senseonics Holdings, Inc. is conducting a public offering of 100 million shares at $0.50 per share, aiming to raise $50 million before expenses [1] Group 1: Offering Details - The public offering is priced at $0.50 per share, with gross proceeds expected to be $50 million [1] - Underwriters have a 30-day option to purchase an additional 15 million shares at the same price [1] - The offering is set to close on May 19, 2025, pending customary closing conditions [1] Group 2: Underwriters - TD Cowen and Barclays are the joint book-running managers for the offering [2] - RBC Capital Markets and Lake Street are acting as bookrunners [2] Group 3: Concurrent Private Placement - Abbott Laboratories will purchase shares in a separate private placement at $0.50 per share, representing 4.99% of Senseonics' outstanding common stock post-offering [4] - The Concurrent Private Placement is expected to close on May 21, 2025, subject to the public offering's closing [4] Group 4: Use of Proceeds - The net proceeds from both the public offering and the Concurrent Private Placement will be used to fund the launch of Eversense 365, ongoing product development, working capital, and general corporate purposes [5] Group 5: Company Overview - Senseonics is focused on developing long-term implantable continuous glucose monitoring systems for diabetes management [7] - The company's products include Eversense® 365 and Eversense® E3, which feature a small sensor that communicates glucose data to a mobile app every 5 minutes [7]

Core Viewpoint - Senseonics Holdings, Inc. has initiated an underwritten public offering of its common stock, with a potential additional 15% of shares available for underwriters to purchase [1][2]. Group 1: Offering Details - The public offering is subject to market conditions and will be made under a "shelf" registration statement filed with the SEC [3]. - TD Cowen and Barclays are the joint book-running managers for the offering, with RBC Capital Markets and Lake Street acting as bookrunners [2]. - A preliminary prospectus supplement will be filed with the SEC and will be accessible on their website [3]. Group 2: Concurrent Private Placement - Abbott Laboratories has agreed to purchase up to $25 million of Senseonics' common stock in a separate private placement, contingent on the public offering's closing [4]. - The net proceeds from both the public offering and the concurrent private placement will be used to support the launch of Eversense 365, ongoing product development, and general corporate purposes [5]. Group 3: Company Overview - Senseonics is focused on developing long-term implantable continuous glucose monitoring systems for diabetes management, with products like Eversense® 365 and Eversense® E3 [8]. - The company's CGM systems feature a small sensor that is implanted under the skin and communicates glucose data to a mobile app every 5 minutes [8].

Group 1 - Senseonics Holdings reported a quarterly loss of $0.02 per share, which is an improvement from a loss of $0.03 per share a year ago, aligning with the Zacks Consensus Estimate [1] - The company posted revenues of $6.26 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 16.84% and showing growth from $5.05 million in the same quarter last year [2] - Senseonics shares have increased approximately 31.8% since the beginning of the year, contrasting with a decline of 4.3% in the S&P 500 [3] Group 2 - The earnings outlook for Senseonics is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.03 on revenues of $6.31 million, and -$0.10 on revenues of $35.66 million for the current fiscal year [7] - The Medical Info Systems industry, to which Senseonics belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]